RxDoctor Payments Data

Walter Ingram, MD

Internal Medicine · Lawrence, KSNPI 1417096389

Payments from drug & device makers

$760in general payments, 2019–2025

Across 44 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$163
  • Amgen$114
  • Lilly USA, LLC$68
  • Pfizer$60
  • GSK$47
  • Astellas Pharma US Inc$43
  • plus $265 from 11 others

What the payments were for

  • Food & beverage$760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$760 in reported general payments places this provider in the 70th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$194,164
Medicare patients
285
Services billed
3,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$104,594
OzempicSemaglutide92$96,545
MounjaroTirzepatide34$38,538
WegovySemaglutide23$32,016
JardianceEmpagliflozin29$30,210
XareltoRivaroxaban31$26,282
JanuviaSitagliptin Phosphate13$16,414
Varenicline Tartrate47$12,646
Janumet XrSitagliptin Phos/Metformin Hcl21$11,777
TradjentaLinagliptin12$9,734
LinzessLinaclotide17$8,907
Repatha SureclickEvolocumab16$8,818
Breo ElliptaFluticasone/Vilanterol20$7,950
VascepaIcosapent Ethyl11$7,324
MyrbetriqMirabegron17$6,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$163$128,561115 claims
PfizerEliquis, Paxlovid$60$106,023128 claims
Lilly USA, LLCMounjaro$68$38,53834 claims
GSKBreo Ellipta, Arnuity Ellipta$47$12,20736 claims
AbbVieLinzess, Synthroid$22$10,30936 claims
Astellas Pharma US IncMyrbetriq$43$6,91117 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$16$5,63813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Lawrence

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →